share_log

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co.维持对Medicenna Therapeutics的买入,将目标股价下调至2.5美元
Benzinga Real-time News ·  2022/11/08 04:03

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $4 to $2.5.

HC Wainwright & Co. 分析师Swayampakula Ramakanth维持Medicenna Therapeutics(纳斯达克股票代码:MDNA)的买入,并将目标股价从4美元下调至2.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发